Drugs in Dev. Endocrinology
Phase II
China 
Lead Product(s) : HDM1002
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002
Details : HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.
Product Name : HDM1002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : HDM1002
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : TCM Healthcare
Deal Size : $107.0 million
Deal Type : Series C Financing
Details : HighTide's lead candidate HTD1801 (berberine ursodeoxycholate), is a novel multifunctional molecule, being developed for the treatment of patients suffering from complex metabolic and digestive diseases.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : TCM Healthcare
Deal Size : $107.0 million
Deal Type : Series C Financing
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022
Details : The data showing positive changes in gut microbiota are encouraging and provide another mechanism of action underlying the beneficial effects of HTD1801 (Berberine Ursodeoxycholate) in liver and metabolic diseases.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The unique design of HTD1801 (berberine ursodeoxycholate) results in its pleiotropic therapeutic effects. Previous Phase 2 study in adults with comorbid nonalcoholic steatohepatitis (NASH) and T2DM completed in the United States demonstrated overall clin...
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : After 14 weeks of treatment, participants receiving 1.8 mg and 2.4 mg XW003 (ecnoglutide) achieved statistically significant mean body weight loss of 8.32 kg (9.6%) and 7.27 kg (9.0%), respectively, compared to 0.62 kg (0.9%) for those receiving placebo ...
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide,Dulaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Least squares mean changes from baseline to week 12 in HbA1c levels were −1.46%, −2.23% and −1.66% for patients receiving IBI362 (mazdutide) in cohort 1,2 and 3, respectively (−1.98% for dulaglutide).
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : Mazdutide,Dulaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HTD1801 is a first-in-class new molecular entity with pleiotropic effects, designed to target both the metabolic pathways critical to the development of T2DM and pathogenic factors underlying liver dysfunction and the progression of NAFLD.
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At week 20, participants receiving 0.4 mg, 0.8 mg, and 1.2 mg XW003 (ecnoglutide) had statistically significant HbA1c reductions from baseline of 1.8%, 1.9% and 2.4%, respectively, compared to 0.5% in participants receiving placebo (P < 0.0001).
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
February 08, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company announced the completion of patient enrollment in Phase 2 trial of XW003 a novel, long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing.
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazdutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI362, novel dual GLP-1 receptor and glucagon receptor agonist, has shown a favorable safety profile in Chinese patients with type 2 diabetes, together with multiple benefits of glycemic control, weight loss and metabolic profiles.
Product Name : IBI362
Product Type : Peptide
Upfront Cash : Inapplicable
August 12, 2021
Lead Product(s) : Mazdutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
